Basilea Pharmaceutica Ltd. reported today that detailed efficacy and safety data of the isavuconazole invasive aspergillosis study were presented at the European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.
http://ift.tt/1llJxh0
http://ift.tt/1llJxh0
No comments:
Post a Comment